AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16218045 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/die
Number of subjects: 50
Study 12119853 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9740203 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of zinc (1200 microg/kg, ratio 4:1)
Number of subjects: 14
Study 9740203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of zinc (300 microg/kg, ratio 1:1)
Number of subjects: 14
Study 9740203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low zinc:iron intake with feeds
Number of subjects: 14
Study 9740203 — intervention group
Group type: EXPERIMENTAL
Intervention: High zinc:iron intake with feeds
Number of subjects: 14
Study 8037087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN) infusion at 10 to 60 micrograms/min for 1 hour, 2 days, or 5 days
Number of subjects: 0
Study 8037087 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary isosorbide dinitrate (ISDN) bolus (1 mg)
Number of subjects: 0
Study 2659876 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (betaloc)
Number of subjects: 30
Study 2659876 — intervention group
Group type: COMPARATOR
Intervention: propranolol (anaprilin)
Number of subjects: 30
Study 29703802 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent early intervention program (home visits, baby massage, and parenting program)
Number of subjects: 233
Study 29703802 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 233
Study 28969715 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual treatment with IVM + ALB
Number of subjects: 0
Study 28969715 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual treatment with IVM + ALB (annual MDA followed by an additional MDA 6 months later)
Number of subjects: 0
Study 28969715 — intervention group
Group type: EXPERIMENTAL
Intervention: Entomological assessments
Number of subjects: 0
Study 28969715 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilaria prevalence assessment
Number of subjects: 0
Study 28969715 — intervention group
Group type: EXPERIMENTAL
Intervention: Community acceptability, feasibility and scale-up evaluation
Number of subjects: 0
Study 25483772 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school‐based health education programme (introducing healthy habits in the curriculum)
Number of subjects: 509
Study 25483772 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 509
Study 24029871 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sodium diet (194±49 mmol Na/day) with lisinopril (40 mg/day)
Number of subjects: 46
Study 24029871 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (102±52 mmol Na/day) with lisinopril (40 mg/day)
Number of subjects: 46
Study 24029871 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sodium diet (194±49 mmol Na/day) with lisinopril plus valsartan (320 mg/day)
Number of subjects: 46
Study 24029871 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (102±52 mmol Na/day) with lisinopril plus valsartan (320 mg/day)
Number of subjects: 46
Study 21393121 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-item simplified food frequency questionnaire (SFFQ)
Number of subjects: 81
Study 21393121 — intervention group
Group type: EXPERIMENTAL
Intervention: SFFQ
Number of subjects: 81
Study 19935615 — intervention group
Group type: EXPERIMENTAL
Intervention: Kimberly‐Clark warming system
Number of subjects: 50
Study 19935615 — intervention group
Group type: COMPARATOR
Intervention: Standard methods of control of body temperature
Number of subjects: 50
Study 17073969 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 17073969 — intervention group
Group type: COMPARATOR
Intervention: Conventional bare metal stents
Number of subjects: 0
Study 15187504 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP/NE infusion (4 units/hr)
Number of subjects: 38
Study 15187504 — intervention group
Group type: COMPARATOR
Intervention: NE infusion only
Number of subjects: 38
Study 15187504 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP/NE infusion
Number of subjects: 38
Study 10937036 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physical activity advice from an exercise specialist
Number of subjects: 299
Study 10937036 — intervention group
Group type: COMPARATOR
Intervention: No advice (control)
Number of subjects: 299
Study 9065344 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 18
Study 9065344 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine hydrochloride 5 mg
Number of subjects: 18
Study 9065344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8091379 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dermatan sulfate (MF701) b.i.d.
Number of subjects: 107
Study 8091379 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dermatan sulfate (MF701) b.i.d.
Number of subjects: 107
Study 8091379 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages of dermatan sulfate (100 mg and 300 mg)
Number of subjects: 107
Study 2517718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin therapy for one week
Number of subjects: 21
Study 2517718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin therapy during hyperosmolar mannitol load
Number of subjects: 21
Study 2517718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin therapy
Number of subjects: 21
Study 1097597 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosleep treatment (24 live treatments)
Number of subjects: 10
Study 1097597 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study 31761477 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto program
Number of subjects: 6691
Study 30711664 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief online engagement-facilitation intervention (EFI) presented prior to an online self-help mental health program (myCompass)
Number of subjects: 693
Study 30711664 — intervention group
Group type: EXPERIMENTAL
Intervention: Active online cognitive behavioral therapy (iCBT) intervention with EFI
Number of subjects: 693
Study 30711664 — intervention group
Group type: EXPERIMENTAL
Intervention: Active online cognitive behavioral therapy (iCBT) intervention without EFI
Number of subjects: 693
Study 30711664 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (arm 3)
Number of subjects: 693
Study 26495881 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Dual Therapy (MDT) with amoxicillin 750 mg thrice daily plus rabeprazole 20 mg thrice daily
Number of subjects: 200
Study 26495881 — intervention group
Group type: COMPARATOR
Intervention: Standard Quadruple Therapy (SQT) with rabeprazole 20 mg b.i.d., bismuth subcitrate 120 mg q.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d.
Number of subjects: 200
Study 26495881 — intervention group
Group type: COMPARATOR
Intervention: Standard Quadruple Therapy (SQT)
Number of subjects: 200
Study 24862395 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPTRC 2.0 with percent free-PSA
Number of subjects: 5826
Study 24862395 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPTRC 2.0 without percent free-PSA
Number of subjects: 5826
Study 24862395 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm biopsies
Number of subjects: 5826
Study 22950390 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine at a dose of 0.3-0.4 μg.kg(‐1).min(‐1)
Number of subjects: 76
Study 22950390 — intervention group
Group type: COMPARATOR
Intervention: Dopamine and/or dobutamine at 2-8 μg.kg(‐1).min(‐1)
Number of subjects: 76
Study 20538369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized 3-item intimate partner violence screen, statements about the unacceptability of violence, risk assessment, and referral by a health professional research assistant
Number of subjects: 399
Study 20538369 — intervention group
Group type: COMPARATOR
Intervention: Usual emergency health care
Number of subjects: 399
Study 18594348 — intervention group
Group type: EXPERIMENTAL
Intervention: ssVEP testing
Number of subjects: 42
Study 18594348 — intervention group
Group type: COMPARATOR
Intervention: psychophysical testing
Number of subjects: 42
Study 16188156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - 80 mg in one dose
Number of subjects: 90
Study 16188156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - repeated epirubicin 40 mg q wk x 4-8 sessions followed by q month to the end of the second year
Number of subjects: 90
Study 16188156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - 50 mg q month to the same duration
Number of subjects: 90
Study 11923800 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone blockade (eplerenone)
Number of subjects: 6200
Study 10845734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 97
Study 10845734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 7625348 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (3%, 6%, 10%, and 14% of energy)
Number of subjects: 63
Study 7625348 — intervention group
Group type: COMPARATOR
Intervention: Monounsaturated fatty acids (17%, 14%, 10%, and 6% of energy)
Number of subjects: 63
Study 2704341 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent aggressive treatment protocols for ALL
Number of subjects: 2093
Study 2704341 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug reinduction program after consolidation
Number of subjects: 2093
Study 408433 — intervention group
Group type: EXPERIMENTAL
Intervention: H. influenzae type b polysaccharide vaccine
Number of subjects: 16000
Study 408433 — intervention group
Group type: EXPERIMENTAL
Intervention: N. meningitidis polysaccharide vaccine
Number of subjects: 16000
Study 30303934 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Maintenance (E + M)
Number of subjects: 55
Study 30303934 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 55
Study 30303934 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 55
Study 27922453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (400 mg twice daily)
Number of subjects: 251
Study 27922453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (800 mg twice daily)
Number of subjects: 251
Study 27922453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (600 mg once daily)
Number of subjects: 251
Study 27922453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (1,200 mg once daily)
Number of subjects: 251
Study 27922453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (various doses)
Number of subjects: 251
Study 27922453 — intervention group
Group type: COMPARATOR
Intervention: ATV/r (ritonavir-boosted atazanavir 300/100 mg once daily)
Number of subjects: 251
Study 24571193 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg methylnaltrexone
Number of subjects: 72
Study 24571193 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 72
Study 23079864 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic (HYP) (FIO2 99.5 %)
Number of subjects: 10
Study 23079864 — intervention group
Group type: COMPARATOR
Intervention: Normoxic (NORM) (FIO2 21 %)
Number of subjects: 10
Study 23079864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HYP and NORM
Number of subjects: 10
Study 21646646 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily for 6 months
Number of subjects: 162
Study 21646646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 19888785 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ 320mg/25mg
Number of subjects: 1329
Study 19888785 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 25mg
Number of subjects: 1329
Study 19888785 — intervention group
Group type: COMPARATOR
Intervention: valsartan 320mg
Number of subjects: 1329
Study 19888785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (valsartan/HCTZ)
Number of subjects: 1329
Study 19888785 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1329
Study 19888785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1329
Study 16920896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1 mg during fasting
Number of subjects: 20
Study 16920896 — intervention group
Group type: COMPARATOR
Intervention: Tesaglitazar 1 mg after a high-fat, high-calorie breakfast
Number of subjects: 20
Study 15545185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily for 3 years
Number of subjects: 299
Study 11430152 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled design
Number of subjects: 0
Study 11430152 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-experimental derivatives
Number of subjects: 0
Study 9261306 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling (n = 14)
Number of subjects: 25
Study 9261306 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment with aqueous humor suppressants (n = 11)
Number of subjects: 25
Study 9261306 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (n = 11)
Number of subjects: 25
Study 8114057 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril
Number of subjects: 30
Study 8114057 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 30
Study 2951019 — intervention group
Group type: EXPERIMENTAL
Intervention: Danggui Shaoyao powder
Number of subjects: 92
Study 31288544 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing intervention (n = 31)
Number of subjects: 59
Study 31288544 — intervention group
Group type: COMPARATOR
Intervention: Painting intervention (n = 28)
Number of subjects: 59
Study 29450827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 462
Study 29450827 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg
Number of subjects: 462
Study 27595812 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program (SFP)
Number of subjects: 292
Study 27595812 — intervention group
Group type: COMPARATOR
Intervention: Minimal control condition
Number of subjects: 292
Study 24173028 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (single oral dose of ∼4.4 × 10(8) CFU)
Number of subjects: 66
Study 24173028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 22851563 — intervention group
Group type: EXPERIMENTAL
Intervention: CRLF2 deregulation (CRLF2‐d)
Number of subjects: 454
Study 22851563 — intervention group
Group type: EXPERIMENTAL
Intervention: IGH@ translocations (IGH@‐t)
Number of subjects: 454
Study 22851563 — intervention group
Group type: EXPERIMENTAL
Intervention: IKZF1 deletions
Number of subjects: 454
Study 22851563 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 454
Study 22851563 — intervention group
Group type: EXPERIMENTAL
Intervention: CRLF2‐d patients
Number of subjects: 454
Study 20465002 — intervention group
Group type: EXPERIMENTAL
Intervention: Grifor vaccine
Number of subjects: 36
Study 20465002 — intervention group
Group type: COMPARATOR
Intervention: Vaxigrip vaccine
Number of subjects: 36
Study 19186329 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber BRAN meal
Number of subjects: 29
Study 19186329 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals rich in saturated fat, oleic acid, and alpha-linolenic acid
Number of subjects: 29
Study 19186329 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals rich in starch and fiber
Number of subjects: 29
Study 19186329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol AUC
Number of subjects: 29
Study 19186329 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 29
Study 15912482 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 36
Study 15912482 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1.0 mg
Number of subjects: 36
Study 12606734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 10 mg once daily for 48 weeks
Number of subjects: 185
Study 12606734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 10947322 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms twice daily) via Pulvinal inhaler
Number of subjects: 72
Study 10947322 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms twice daily) via Diskhaler inhaler
Number of subjects: 72
Study 10947322 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Pulvinal and Diskhaler)
Number of subjects: 72
Study 8874327 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU 450 mg/m2 as an intravenous bolus with FA 200 mg/m2 in 500 mL 0.9% normal saline solution in 2‐hour infusion (Group A)
Number of subjects: 106
Study 8874327 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 450 mg/m2 as an intravenous bolus with FA 200 mg/m2 in 500 mL 0.9% normal saline solution in 2‐hour infusion plus IFN 2b 5 million units subcutaneously three times weekly (Group B)
Number of subjects: 106
Study 8874327 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU and FA (Group A)
Number of subjects: 106
Study 8874327 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU and FA plus IFN 2b (Group B)
Number of subjects: 106
Study 8874327 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 2b (Group B)
Number of subjects: 106
Study 2005734 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper diapers
Number of subjects: 141
Study 2005734 — intervention group
Group type: COMPARATOR
Intervention: Double cloth diapers with plastic overpants
Number of subjects: 141
Study 2005734 — intervention group
Group type: COMPARATOR
Intervention: Clothes worn over diapers
Number of subjects: 141
Study 2005734 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooms with diarrhea occurrences
Number of subjects: 141
Study 6421004 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion
Number of subjects: 104
Study 30347425 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE)
Number of subjects: 206
Study 30347425 — intervention group
Group type: COMPARATOR
Intervention: Carcinoembryonic antigen (CEA)
Number of subjects: 206
Study 30347425 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 206
Study 30071993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1,000 mg twice a day
Number of subjects: 1012
Study 30071993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012
Study 25493621 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intracameral bevacizumab
Number of subjects: 71
Study 25493621 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution as placebo
Number of subjects: 71
Study 25024657 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based sleep education program (4 sessions of 50 minutes each)
Number of subjects: 29
Study 25024657 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 29
Study 22206782 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual training combined with agility drills
Number of subjects: 0
Study 22206782 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility drills only
Number of subjects: 0
Study 22206782 — intervention group
Group type: COMPARATOR
Intervention: Control group following ACSM exercise recommendations
Number of subjects: 0
Study 19515291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 53
Study 18032884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder dissolved in water (CC-W)
Number of subjects: 21
Study 18032884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder dissolved in milk (CC-M)
Number of subjects: 21
Study 18032884 — intervention group
Group type: COMPARATOR
Intervention: Whole milk (M-c)
Number of subjects: 21
Study 15068963 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked hyperglycemia (15 mM) during gastric distension
Number of subjects: 0
Study 15068963 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological hyperglycemia (8 mM) during gastric distension
Number of subjects: 0
Study 15068963 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (5 mM) during gastric distension
Number of subjects: 0
Study 11784454 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily for 12 weeks)
Number of subjects: 111
Study 11784454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 12 weeks)
Number of subjects: 111
Study 9770654 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-only rotational testing (HORT) with visual fixation
Number of subjects: 0
Study 9770654 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-only rotational testing (HORT) without visual fixation
Number of subjects: 0
Study 9770654 — intervention group
Group type: EXPERIMENTAL
Intervention: Active head movement during HORT
Number of subjects: 0
Study 9770654 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive head movement during HORT
Number of subjects: 0
Study 9770654 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual fixation during HORT
Number of subjects: 0
Study 9770654 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy young control subjects
Number of subjects: 0
Study 8149802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein patch
Number of subjects: 209
Study 8149802 — intervention group
Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 209
Study 3061823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/mq i.v. every 3 weeks) + 5‐fluorouracil (600 mg/mq i.v. bolus/weekly)
Number of subjects: 60
Study 3061823 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil alone (same schedule)
Number of subjects: 60
Study 26218236 — intervention group
Group type: EXPERIMENTAL
Intervention: PREG-LT (Pregnenolone 50 mg/day + L-Theanine 400 mg/day)
Number of subjects: 40
Study 26218236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27701170 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (BBs) at baseline
Number of subjects: 2538